Lack of Clinical Benefit of Andexanet Flummoxes FDA Panel
MedPage Today) — FDA advisors pushed for nuance in discussing whether andexanet alfa (Andexxa) should gain full approval, citing uncertainties about which dose and in which patients it could be best used to stop bleeding. Members of the Cellular…
MedPage Today) — FDA advisors pushed for nuance in discussing whether andexanet alfa (Andexxa) should gain full approval, citing uncertainties about which dose and in which patients it could be best used to stop bleeding.
Members of the Cellular…
Read More
About Author
